Internal Medicine, Medical Oncology · Fort Myers, FL
NPI
1245221993
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
8981 Colonial Center Dr
Fort Myers, FL, 33905
Phone (239) 938-0800
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.8M
131,686 services
Medicare patients, 2024
853
Average age 76
Drug cost, 2024
$5.9M
1,900 prescriptions
Company payments, 2025
$8,555
From 46 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lowell L Hart was code J9271 (injection, pembrolizumab, 1 mg), 17,400 times for 22 patients. In total Lowell L Hart billed 131,686 services in 151 codes, and Medicare paid $2.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 17,400 | 22 | $44.60 | $776K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 13,770 | 18 | $0.28 | $3,890 |
| J0897 Injection, denosumab, 1 mg | Office | 5,640 | 46 | $20.57 | $116K |
| J1756 Injection, iron sucrose, 1 mg | Office | 5,200 | 17 | $0.17 | $883 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 3,510 | 21 | $6.37 | $22K |
| J0185 Injection, aprepitant, 1 mg | Office | 3,250 | 12 | $1.34 | $4,357 |
| 85025 Blood Count | Office | 1,534 | 546 | $7.57 | $12K |
| 36415 Venipuncture Blood Collection | Office | 1,418 | 536 | $8.65 | $12K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,114 | 48 | $0.09 | $101 |
| 99213 Office E&M - Established | Office | 655 | 395 | $63.28 | $41K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 630 | 27 | $0.71 | $449 |
| 99214 Office E&M - Established | Office | 625 | 252 | $95.22 | $60K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 485 | 12 | $3.50 | $1,696 |
| 96372 Injection Administration | Office | 445 | 165 | $10.92 | $4,860 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 344 | 16 | $0.07 | $25.48 |
By year: 2022 $2.4M for 132,591 services; 2023 $2.1M for 135,314 services; 2024 $2.8M for 131,686 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,534 | 546 | $7.57 | $12K |
| 36415 Venipuncture Blood Collection | 1,418 | 536 | $8.65 | $12K |
| 81003 Clinical Chemistry | 38 | 24 | $2.20 | $83.6 |
| 85045 Blood Count | 18 | 15 | $3.91 | $70.38 |
Medicare prescription drug claims, 2024
In 2024, the drug Lowell L Hart prescribed most often to Medicare patients was Letrozole, with 345 prescriptions and refills. In total Lowell L Hart wrote 1,900 Medicare prescriptions that cost $5.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 345 | 844 | 99 | $7,872 |
| Anastrozole Generic | 161 | 413 | 44 | $2,583 |
| Levothyroxine Sodium Generic | 100 | 209 | 26 | $535 |
| Eliquis Apixaban | 82 | 104 | 23 | $60K |
| Ondansetron Odt Ondansetron | 70 | 70 | 37 | $1,078 |
| Revlimid Lenalidomide | 61 | 61 | Under 11 | $1.1M |
| Prochlorperazine Maleate Generic | 55 | 55 | 15 | $678 |
| Prednisone Generic | 54 | 64 | 33 | $161 |
| Ibrance Palbociclib | 49 | 49 | Under 11 | $655K |
| Exemestane Generic | 41 | 115 | 13 | $9,148 |
| Calquence Acalabrutinib Maleate | 40 | 40 | Under 11 | $400K |
| Dexamethasone Generic | 40 | 59 | 25 | $827 |
| Xarelto Rivaroxaban | 39 | 53 | Under 11 | $29K |
| Brukinsa Zanubrutinib | 34 | 34 | Under 11 | $287K |
| Potassium Chloride Generic | 32 | 34 | Under 11 | $133 |
Brand drugs: 608 claims; generic drugs: 1,292 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lowell L Hart $8,555 ($8,048 in general payments such as food, travel and fees and $507 for research) from 46 companies. The largest payer was Novartis Pharmaceuticals Corporation with $3,596.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 15 | $3,596 |
| AstraZeneca Pharmaceuticals LP AZN | 14 | $1,476 |
| Merck Sharp & Dohme LLC MRK | 14 | $404 |
| Pfizer Inc. PFE | 18 | $364 |
| Celgene Corporation BMY | 10 | $266 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 20 | $205 |
| Exelixis Inc. EXEL | 4 | $182 |
| Pharmacosmos Therapeutics Inc. | 3 | $156 |
| Dendreon Pharmaceuticals LLC | 3 | $136 |
| Legend Biotech USA Inc. LEGN | 4 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.